Proveca medicines for children
This section is only for Healthcare Professionals and relates to paediatric medicine developed and licensed by Proveca. Proveca also invests in the provision of educational items which are listed on the side menu, these can be given to carers and patients by Healthcare Professionals.
(320mcg/ml glycopyrronium equivalent to 400mcg/ml glycopyrronium bromide)
Sialanar® received a Paediatric Use Marketing Authorisation (PUMA) in September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children aged 3 years and older with chronic neurological disorders.
Reviewed November 2021